



Contact:

Robert Erwin
President
iBio, Inc.
302-355-2335
rerwin@ibioinc.com

Melody Carey
Co-President
Rx Communications, Inc.
917-322-2571
mcarey@rxir.com

FOR IMMEDIATE RELEASE

**iBio to Present Advantages of Plant-Based Vaccine Manufacturing at
International Association for Biologicals Conference**

*Innovative use of green plant technology becoming leading alternative to slower and more costly
vaccine production methods*

Wilmington, DE – October 12, 2009 – iBio, Inc. (OTCBB: IBPM), a biotechnology company focused on developing vaccines and therapeutic proteins for the treatment of infectious diseases, is presenting today at the International Association for Biologicals New Cells for New Vaccines IV Conference in Wilmington, DE. Robert L. Erwin, iBio’s president, will present, *Plant-Based Vaccine Manufacturing: Saving Time & Money—Enhancing Regional Autonomy*.

The oral presentation will cover iBio’s unique application of its iBioLaunch™ platform technology in creating a lower-cost, more efficient method of vaccine manufacturing versus conventionally produced vaccines.

“Although conventionally produced vaccines have contributed greatly to reducing the health burden of many infectious diseases, we are finding that newer methods used in the production of a wide variety of proteins in green plants are increasingly becoming more practical in the development of vaccines,” stated Robert Erwin. “The efficiency and relatively low capital costs of implementing modern, plant-based vaccine manufacturing processes have important implications for enabling worldwide regional autonomy in vaccine production.”

About iBio, Inc.

iBio, Inc. is a biotechnology company focused on developing vaccines and therapeutic proteins based upon our proprietary plant-based iBioLaunch™ Platform Technology. The Company’s near-term focus is to advance an H1N1 influenza vaccine candidate to clinical trials and to establish business arrangements for use of the technology by licensees for the development and production of other products for the prevention and treatment of various infectious diseases including influenza, anthrax and human papilloma virus (HPV). In 2003, iBio entered into a research and development agreement with the Fraunhofer USA Center for Molecular Biotechnology (FhCMB), a leading not-for-profit translational research institution, and has exclusive rights to the proprietary platform developed under the agreement for human health

applications for developing vaccines and therapeutic products for a broad range of medical indications and for veterinary applications of plant-based influenza vaccines. For additional information please visit www.ibioinc.com.

Safe Harbor Statement Under the Private Securities Litigation Reform Act of 1995:

Statements included in this release related to iBio, Inc. may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements involve a number of risks and uncertainties such as competitive factors, technological development, market demand, and the Company's ability to obtain new contracts and accurately estimate net revenues due to variability in size, scope and duration of projects. Further information on potential risk factors that could affect the Company's financial results can be found in the company's Reports filed with the Securities and Exchange Commission.

###